Sunshine Biopharma (SBFM) Revenue (2015 - 2026)

Sunshine Biopharma has reported Revenue for 10 years, with the latest figure at $8.1 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue fell 9.13% year-over-year to $8.1 million; the trailing twelve-month figure through Mar 2026 stood at $35.5 million (down 2.05% YoY), and the FY2025 full-year result was $36.3 million, up 4.11% from the prior year.
• Revenue for Q1 2026 stood at $8.1 million, down from $8.6 million in the prior quarter.
• The five-year high for Revenue was $9.6 million in Q4 2024, with the low at $122645.0 in Q1 2022.
• Historically, Revenue has averaged $6.3 million across 5 years, with a median of $7.7 million in 2023.
• Annual changes were most pronounced in 2022 — Revenue jumped 4528.68% — and 2025, when it slipped 10.61%.
• Sunshine Biopharma's Revenue stood at $3.9 million in 2022, then soared by 94.94% to $7.7 million in 2023, then rose by 24.93% to $9.6 million in 2024, then fell by 10.61% to $8.6 million in 2025, then fell by 5.69% to $8.1 million in 2026.
• The last three Revenue figures came in at $8.1 million (Q1 2026), $8.6 million (Q4 2025), and $9.4 million (Q3 2025), per Business Quant data.